OBJECTIVE: IL-10 is a potent anti-inflammatory cytokine, and IL-10-producing regulatory T cells are effective inhibitors of murine asthmatic responses. This study determined whether IL-10-dependent mechanisms mediated the local inhalational tolerance seen with chronic inhalational exposure to antigen. METHODS: Wildtype and IL-10(-/-) mice were sensitized with ovalbumin (OVA) and then challenged with daily OVA inhalations for 10 days or 6 weeks. RESULTS: The 10-day animals developed allergic airway disease, characterized by BAL eosinophilia, histologic airway inflammation and mucus secretion, methacholine hyperresponsiveness, and OVA-specific IgE production. These changes were more pronounced in IL-10(-/-) mice. The 6-week IL-10(-/-) and wildtype animals both developed inhalational tolerance, with resolution of airway inflammation but persistence of OVA-specific IgE production. CONCLUSION: IL-10 may have anti-inflammatory effects in the acute stage of murine allergic airways disease, but the cytokine does not mediate the development of local inhalational tolerance with chronic antigen exposure.
OBJECTIVE:IL-10 is a potent anti-inflammatory cytokine, and IL-10-producing regulatory T cells are effective inhibitors of murine asthmatic responses. This study determined whether IL-10-dependent mechanisms mediated the local inhalational tolerance seen with chronic inhalational exposure to antigen. METHODS: Wildtype and IL-10(-/-) mice were sensitized with ovalbumin (OVA) and then challenged with daily OVA inhalations for 10 days or 6 weeks. RESULTS: The 10-day animals developed allergic airway disease, characterized by BAL eosinophilia, histologic airway inflammation and mucus secretion, methacholine hyperresponsiveness, and OVA-specific IgE production. These changes were more pronounced in IL-10(-/-) mice. The 6-week IL-10(-/-) and wildtype animals both developed inhalational tolerance, with resolution of airway inflammation but persistence of OVA-specific IgE production. CONCLUSION:IL-10 may have anti-inflammatory effects in the acute stage of murineallergic airways disease, but the cytokine does not mediate the development of local inhalational tolerance with chronic antigen exposure.
Authors: L Faustino; D M Fonseca; E B Florsheim; R R Resende; A P Lepique; E Faquim-Mauro; E Gomes; J S Silva; H Yagita; M Russo Journal: Mucosal Immunol Date: 2014-02-26 Impact factor: 7.313
Authors: Joshua J Pothen; Matthew E Poynter; Lennart K A Lundblad; Jason H T Bates Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-03-04 Impact factor: 5.464
Authors: Stephanie H Polukort; Jeffrey Rovatti; Logan Carlson; Chelsea Thompson; Jennifer Ser-Dolansky; Shannon R M Kinney; Sallie S Schneider; Clinton B Mathias Journal: J Immunol Date: 2016-05-06 Impact factor: 5.422
Authors: William F Carson; Linda A Guernsey; Anurag Singh; Anthony T Vella; Craig M Schramm; Roger S Thrall Journal: Int Arch Allergy Immunol Date: 2007-10-04 Impact factor: 2.749
Authors: Anurag Singh; William F Carson; Eric R Secor; Linda A Guernsey; Richard A Flavell; Robert B Clark; Roger S Thrall; Craig M Schramm Journal: J Immunol Date: 2008-06-01 Impact factor: 5.422
Authors: Eric R Secor; William F Carson; Anurag Singh; Mellisa Pensa; Linda A Guernsey; Craig M Schramm; Roger S Thrall Journal: Evid Based Complement Alternat Med Date: 2008-03 Impact factor: 2.629
Authors: Steven M Szczepanek; Eric R Secor; Sonali J Bracken; Linda Guernsey; Ektor Rafti; Adam Matson; Roger S Thrall; Biree Andemariam Journal: Pediatr Res Date: 2013-05-31 Impact factor: 3.756